Identification of new methods for drug candidates for Alzheimer's disease

Old age is the biggest risk factor for many diseases, including Alzheimer's disease and cancer. Geroprotectors is a recently discovered class of anti-aging compounds. The New Salk study has now identified a unique subsequon of these compounds, called geostitric protectors, that are candidates for Alzheimer's disease that slow the aging process in mice.
The argument is that if you can extend the lifespan of model organisms, such as mice, and translate this effect into humans, you should be able to slow down the emergence of many aging-related diseases, such as Alzheimer's, Parkinson's disease, cancer, and overall weakness," said Professor Salk and Dave Schubert, director of the Salk Cell Neurobiology Laboratory.
the study, published November 13, 2018 in the journal Trends in Pharmacology, was conducted in collaboration with Pamela Maher, a senior staff scientist at Salk, who is a senior author of the study in the Department of Cell Neurobiology. The team began using two chemicals found in plants with medicinal properties: fisetin, a natural product from fruits and vegetables, and curculin from curcub, the curry spice. As a result, the team synthesized three Alzheimer's drug candidates based on their ability to protect neurons from the multiple toxicity associated with the aging brain. Laboratory results show that these three synthetic candidates (known as CMS121, CAD31 and J147), as well as non-cersone and curcubin, reduce molecular markers of aging and dementia and extend the life of mice or flies. Importantly, the team demonstrated that these Alzheimer's drug candidates use the same molecular pathways as two other well-researched synthetic compounds that are known to extend the lifespan of many animals. For this reason and based on the results of their previous studies, the team said that non-cersone, curculin and three Alzheimer's disease candidates all met the definition of geostational protectors. The team is now focused on integrating two geostartic protectors into human clinical trials. The fisetin derivative CMS121 is currently in animal toxicology studies required by the FDA to approve the start of clinical trials. Curcubin derivative J147 is under FDA review to allow clinical trials of Alzheimer's disease to begin early next year. The team plans to incorporate biomarkers for aging into clinical trials to determine potential geological protection. "Since we found that natural products curcubin and non-cersone are also geostenterative protectors and can be purchased as supplements, they can now offer some therapeutic benefits." Maher said.
in the Lab are determining whether these compounds have an effect on organs outside the brain. If these drugs are beneficial to other body systems, such as maintaining kidney function and overall muscle health, they can be used to treat or prevent aging diseases. Schubert said.
researchers say the findings of these Alzheimer's drug candidates confirm that the drug discovery model they developed is a reasonable way to identify other geostational protector compounds that contribute to healthy aging. This can greatly accelerate the pipeline of drugs used to treat aging diseases that are currently incurable. (This net special draft)